Nishida, Toshirou
,
Sakai, Yoshiharu
Takagi, Masakazu
Ozaka, Masato
Kitagawa, Yuko
Kurokawa, Yukinori
Masuzawa, Toru
Naito, Yoichi
Kagimura, Tatsuo
Hirota, Seiichi
Funding for this research was provided by:
Aviation and Missile Research, Development, and Engineering Center (28-A-16)
Article History
Received: 17 February 2019
Accepted: 15 April 2019
First Online: 30 April 2019
Compliance with ethical standards
:
: Yuko Kitagawa, Toru Masuzawa, Tatsuo Kagimura, and Masakazu Takagi have no COI in terms of Employment, Leadership, Stock and Other Ownership Interests, Honoraria, Consulting or Advisory Role, Speakers’ Bureau, Research Funding, Patents, Royalties, Other Intellectual Property, Expert Testimony, Travel, Accommodations, Expenses and Other Relationship. Toshirou Nishida has been paid Honoraria by Pfizer, Bayer, Eizai, and Taiho. Seiichi Hirota has been paid Honoraria by Novartis and Pfizer. Yoichi Naito has Consulting or Advisory Role for Pfizer, Eisai, Eli Lilly, Chugai, Novartis, and AstraZeneca, Speakers' Bureau of Pfizer, Novartis, Chugai, Eisai, AstraZeneca, Shionogi, Hisamitus, Fuji RI farma, JSMO, and Technical Information Institute, and Research Funding form AstraZeneca, Eli Lilly, Pfizer, Ono, Taiho, CSPOR-BC, and JBCRG. Yukinori Kurokawa has been paid Honoraria by Taiho, Eli Lilly, Yakult Honsha, Ono, MSD, Kaken Pharmaceutical, Medtronic, Johnson & Johnson, and Stryker. Yoshiharu Sakai has Speakers’ Bureau of Taiho, Chugai, Tsumura, Yakult, Sanofi, and MSD, and Research Funding from Taiho, Chugai, Yaklut, and Sanofi. Masato Ozaka has been paid Honoraria by Taiho, Yakult, Novartis, Bayer, Pfizer, and Takeda, and has Research Funding from Baxalta, Taiho, Incyte, and Boston biomedical. The others have no COI to declare.